Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors

Background VCN-01 is an oncolytic adenovirus (Ad5 based) designed to replicate in cancer cells with dysfunctional RB1 pathway, express hyaluronidase to enhance virus intratumoral spread and facilitate chemotherapy and immune cells extravasation into the tumor. This phase I clinical trial was aimed t...

Full description

Bibliographic Details
Main Authors: Gabriel Capellá, Francisco X Real, Marta Gil-Martin, Rocio Garcia-Carbonero, Rafael Moreno, Ramon Alemany, Martí Farrera-Sal, Ramon Salazar, Teresa Macarulla, Jaime Martinez de Villarreal, Natalia del Pozo, Carmen Guillén-Ponce, Miriam Bazan-Peregrino, Rafael Álvarez, Ana Mato-Berciano, Emma Blasi, Carmen Blasco, Manel Cascallo, Maria C Riesco-Martinez, Helena Verdaguer, Maria Victoria Maliandi, Silvia Torres-Manjon, Marcel Costa, Noemí Vidal
Format: Article
Language:English
Published: BMJ Publishing Group 2022-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/3/e003255.full

Similar Items

Similar Items